阿比特龙治疗前列腺癌的疗效和安全性的meta分析  

Efficacy and Safety of Abiraterone in the Treatment of Prostate Cancer:A Meta-Analysis

作　　者：雷乃军 谭政[2] 李曾[2] 祝德[1] 张军旗[1] Lei Naijun;Tan Zheng;Li Zeng;Zhu De;Zhang Junqi(Department of Oncology,Bazhong Central Hospital,Bazhong 636000,Sichuan,China;Department of Urology,Sichuan Clinical Research Center for Cancer,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China)

机构地区：[1]巴中市中心医院肿瘤科,四川636000 [2]四川省肿瘤医院·研究所,四川省肿瘤临床医学研究中心,四川省癌症防治中心,电子科技大学附属肿瘤医院,成都610041

出　　处：《肿瘤预防与治疗》2025年第1期33-41,共9页Journal of Cancer Control And Treatment

基　　金：四川省科技厅重点研发计划项目(编号:2020YFS0421)。

摘　　要：目的:系统评价阿比特龙治疗前列腺癌(prostate cancer,PC)的疗效和安全性。方法:全面检索Pubmed、WanFang Data、ClinicalTrials、CNKI、Embase等中英文数据库,收集建库至2023年8月期间发表的有关阿比特龙治疗PC的RCT研究;提取符合纳入要求研究中的与疗效和安全性相关的有效数据,并以RevMan5.3软件行Meta分析;对比主要以阿比特龙治疗的阿比特龙组和其他药物治疗的对照组无进展生存期(progression-free survival,PFS)、前列腺特异性抗原(prostate-specific antigen,PSA)水平、有效率、PSA反应率、不良反应率。结果:纳入研究10项,研究病例共6439例。Meta分析结果显示,2组PFS对比,阿比特龙组长于对照组(SMD=1.975;95%CI:1.505~2.445;Z=8.240;P<0.001);PSA水平对比,阿比特龙组均低于对照组(SMD=-1.283;95%CI:-2.120~-0.446;Z=3.000;P=0.003);有效率及PSA反应率对比,阿比特龙组均高于对照组(有效率:OR=3.720;95%CI:3.080~4.503;Z=13.570;P<0.001;PSA反应率:OR=3.099;95%CI:1.380~6.962;Z=2.740;P=0.006),不良反应率对比,阿比特龙组低于对照组(OR=0.356;95%CI:0.187~0.678;Z=3.140;P=0.002)。结论:阿比特龙用于PC治疗疗效确切,可有效控制去势抵抗性PC患者的疾病进展,延长其生存时间,且可明显减轻不良反应,安全性更高。Objective:To systematically evaluate the efficacy and safety of abiraterone in the treatment of prostate cancer.Methods:We comprehensively searched Pubmed,WanFang Data,ClinicalTrials,CNKI,Embase and other Chinese and English databases,and collected the RCT studies on abiraterone in the treatment of prostate cancer published up until August 2023.Effective data related to efficacy and safety were extracted from studies that met the inclusion requirements,and meta-analysis was performed using RevMan5.3 software.Progression-free survival(PFS),prostate-specific antigen(PSA)level,effective rate,PSA response rate,and adverse reaction rate were compared between the abiraterone group and control group.Results:6,439 cases from 10 studies were included.The results of meta-analysis showed that the abiraterone group was longer in PFS than the control group(SMD=1.975,95%CI:1.505~2.445,Z=8.240,P<0.001);the level of PSA in the abiraterone group was lower than that in control group(SMD=-1.283,95%CI:-2.120~-0.446,Z=3.000,P=0.003);the effective rate and PSA response rate in the abiraterone group were higher than those in control group(0R=3.724,95%CI:3.080~4.503,Z=13.570,P<0.001;OR=3.099,95%CI:1.380~6.962,Z=2.740,P=0.006);the adverse reaction rate in the abiraterone group was lower than that in control group(0R=0.356,95%CI:0.187~0.678,Z=3.140,P=0.002).Conclusion:Abiraterone is effective and safe in the treatment of prostate cancer,it can effectively prevent the progression of castration-resistant prostate cancer,prolong the survival time of patients and significantly reduce adverse reactions.

关 键 词：阿比特龙 前列腺癌 疗效 META分析 安全性 

分 类 号：R737.25[医药卫生—肿瘤]